The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity
Open accessAbstract
CD8+ T cells are critical for elimination of cancer cells. Factors within the tumor microenvironment (TME) can drive these cells to a hypofunctional state known as exhaustion. The most terminally exhausted T (tT ex) cells are resistant to checkpoint blockade immunotherapy and might instead limit immunotherapeutic efficacy. Here we show that intratumoral CD8+ tT ex cells possess transcriptional features of CD4+Foxp3+ regulatory T cells and are similarly capable of directly suppressing T cell proliferation ex vivo. tT ex cell suppression requires CD39, which generates immunosuppressive adenosine. Restricted deletion of CD39 in endogenous CD8+ T cells resulted in slowed tumor progression, improved immunotherapy responsiveness and enhanced infiltration of transferred tumor-specific T cells. CD39 is induced on tT ex cells by tumor hypoxia, thus mitigation of hypoxia limits tT ex suppression. Together, these data suggest tT ex cells are an important regulatory population in cancer and strategies to limit their generation, reprogram their immunosuppressive state or remove them from the TME might potentiate immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Independent of glycolysis, the HIFs can induce the production of immunosuppressive metabolites such as adenosine by transcriptionally activating ectoenzymes such as ENTPD2/CD39L1, CD39, and CD73 (Table 1), which contribute to the multistep conversion of extracellular ATP through ADP/AMP to adenosine, thus promoting the maintenance of MDSCs, which limits the activity of immune checkpoint inhibitors”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [92]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D. J., Usheva, A., Erat, A., Chen, J., Enjyoji, K., Linden, J. M., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,613
Self-citationMolecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30789-x · Cited by 2,075
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Blank, C. U., Haining, W. N., Held, W., Hogan, P. G., Kallies, A., Lugli, E., Lynn, R. C., Philip, M., Rao, A., Restifo, N. P., et al. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0221-9 · Cited by 1,603
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
Watson, M. J., Vignali, P., Mullett, S. J., Overacre-Delgoffe, A. E., Peralta, R. M., Grebinoski, S., Menk, A. V., Rittenhouse, N., DePeaux, K., Whetstone, R. D., et al. (2021) · Nature · doi:10.1038/s41586-020-03045-2 · Cited by 1,298
Self-citationGranzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor Clearance
Cao, X., Cai, S. F., Fehniger, T. A., Song, J., Collins, L. I., Piwnica-Worms, D. R., & Ley, T. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.08.014 · Cited by 1,117
Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response
McKeown, S. R. (2014) · The British Journal of Radiology · doi:10.1259/bjr.20130676 · Cited by 1,050
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Duhen, T., Duhen, R., Montler, R., Moses, J., Moudgil, T., de Miranda, N. F., Goodall, C. P., Blair, T. C., Fox, B. A., McDermott, J. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05072-0 · Cited by 938
Scharping, N. E., Rivadeneira, D. B., Menk, A. V., Vignali, P. D. A., Ford, B. R., Rittenhouse, N. L., Peralta, R., Wang, Y., Wang, Y., DePeaux, K., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00834-9 · Cited by 897
Self-citationCooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Jin, H.-T., Anderson, A. C., Tan, W. G., West, E. E., Ha, S.-J., Araki, K., Freeman, G. J., Kuchroo, V. K., & Ahmed, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009731107 · Cited by 858
Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733
Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen
Doedens, A. L., Phan, A. T., Stradner, M. H., Fujimoto, J. K., Nguyen, J. V., Yang, E., Johnson, R. S., & Goldrath, A. W. (2013) · Nature Immunology · doi:10.1038/ni.2714 · Cited by 660
Metabolic barriers to cancer immunotherapy
DePeaux, K., & Delgoffe, G. M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00541-y · Cited by 626
Self-citationAdaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion
Sawant, D. V., Yano, H., Chikina, M. D., Zhang, Q., Liao, M., Liu, C., Callahan, D. J., Sun, Z., Sun, T., Tabib, T., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0346-9 · Cited by 569
Self-citationEfficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Scharping, N. E., Menk, A. V., Whetstone, R. D., Zeng, X., & Delgoffe, G. M. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0103 · Cited by 520
Self-citationMenk, A. V., Scharping, N. E., Moreci, R. S., Zeng, X., Guy, C. S., Salvatore, S. R., Bae, H. R., Xie, J., Young, H. A., Wendell, S. G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.040 · Cited by 496
Self-citationMetabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
Guo, Y., Xie, Y., Gao, M., Zhao, Y., Franco, F., Wenes, M., Siddiqui, I., Bevilacqua, A., Wang, H., Yang, H., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00940-2 · Cited by 455
Perrot, I., Michaud, H., Giraudon‐Paoli, M., Augier, S., Docquier, A., Gros, L., Courtois, R., Déjou, C., Jecko, D., Becquart, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.091 · Cited by 439
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells
Canale, F. P., Ramello, M. C., Núñez, N. G., Furlan, C. L. A., Bossio, S., Serrán, M. G., Tosello, J., del Castillo, A., Ledesma, M., Sedlik, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2684 · Cited by 413
Jayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C., Nicholas, C., Jaiswal, A. R., Sun, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96268 · Cited by 399
CD39 Expression Identifies Terminally Exhausted CD8+ T Cells
Gupta, P., Godec, J., Wolski, D., Adland, E., Yates, K. B., Pauken, K. E., Cosgrove, C., Ledderose, C., JUNGER, W. G., Robson, S. C., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005177 · Cited by 384
Self-citationAdenosine Metabolism: Emerging Concepts for Cancer Therapy
Boison, D., & Yegutkin, G. G. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.007 · Cited by 346
IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity
Oft, M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0214 · Cited by 322
Schuler, P. J., Saze, Z., Hong, C.-S., Müller, L., Gillespie, D. G., Cheng, D., Harasymczuk, M., Mandapathil, M., Lang, S., Jackson, E. K., et al. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12354 · Cited by 277
Naing, A., Infante, J. R., Papadopoulos, K. P., Chan, I. H., Shen, C., Ratti, N. P., Rojo, B., Autio, K. A., Wong, D. J. L., Patel, M. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.007 · Cited by 258
KIR + CD8 + T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19
Li, J., Zaslavsky, M., Su, Y., Guo, J., Sikora, M. J., van Unen, V., Christophersen, A., Chiou, S.-H., Chen, L., Li, J., et al. (2022) · Science · doi:10.1126/science.abi9591 · Cited by 249
Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma
Najjar, Y. G., Menk, A. V., Sander, C., Rao, U. N. M., Karunamurthy, A. D., Bhatia, R., Zhai, S., Kirkwood, J. M., & Delgoffe, G. M. (2019) · JCI Insight · doi:10.1172/jci.insight.124989 · Cited by 240
Self-citationCollier, J. L., Weiss, S. A., Pauken, K. E., Sen, D. R., & Sharpe, A. H. (2021) · Nature Immunology · doi:10.1038/s41590-021-00949-7 · Cited by 237
Seo, N., HAYAKAWA, S., Takigawa, M., & Tokura, Y. (2001) · Immunology · doi:10.1046/j.1365-2567.2001.01279.x · Cited by 205
Horton, B. L., Williams, J. B., Cabanov, A., Spranger, S., & Gajewski, T. F. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0249 · Cited by 170
Magnuson, A. M., Kiner, E., Ergün, A., Park, J. S., Asinovski, N., Ortiz-Lopez, A., Kilcoyne, A., Paoluzzi-Tomada, E., Weissleder, R., Mathis, D. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810580115 · Cited by 151
Hanna, B. S., Cid, L. L., Iskar, M., Roessner, P. M., Klett, L. C., Wong, J., Paul, Y., Ioannou, N., Öztürk, S., Mack, N. L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.004 · Cited by 137
On the mechanism of anti-CD39 immune checkpoint therapy
Allard, D., Allard, B., & Stagg, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000186 · Cited by 136
Zandberg, D. P., Menk, A. V., Velez, M., Normolle, D., DePeaux, K., Liu, A., Ferris, R. L., & Delgoffe, G. M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002088 · Cited by 119
Self-citationFord, B. R., Vignali, P., Rittenhouse, N., Scharping, N. E., Peralta, R. M., Lontos, K., Frisch, A. T., Delgoffe, G. M., & Poholek, A. C. (2022) · Science Immunology · doi:10.1126/sciimmunol.abj9123 · Cited by 112
Self-citationLee, Y. G., Guruprasad, P., Ghilardi, G., Pajarillo, R., Sauter, C. T., Patel, R. P., Ballard, H. J., Hong, S. J., Chun, I., Yang, N., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1026 · Cited by 99
The role of NK cells and CD39 in the immunological control of tumor metastases
Zhang, H., Vijayan, D., Li, X.-Y., Robson, S. C., Geetha, N., Teng, M. W. L., & Smyth, M. J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593809 · Cited by 88
Self-citationHypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy
Jayaprakash, P., Vignali, P., Delgoffe, G. M., & Curran, M. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-060619-022830 · Cited by 87
Self-citationRivas, J. R., Liu, Y., Alhakeem, S. S., Eckenrode, J. M., Martí, F., Collard, J. P., Zhang, Y., Shaaban, K. A., Muthusamy, N., Hildebrandt, G. C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01217-1 · Cited by 66
CD39 – A bright target for cancer immunotherapy
Guo, S., Han, F., & Zhu, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113066 · Cited by 57
Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer
Pfannenstiel, L. W., Diaz-Montero, C. M., Tian, Y. F., Scharpf, J., Ko, J. S., & Gastman, B. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0054 · Cited by 49
Genetically driven CD39 expression shapes human tumor‐infiltrating CD8 + T‐cell functions
Gallerano, D., Ciminati, S., Grimaldi, A., Piconese, S., Cammarata, I., Focaccetti, C., Pacella, I., Accapezzato, D., Lancellotti, F., Sacco, L., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33131 · Cited by 41
Tøndell, A., Wahl, S. G. F., Sponaas, A., Sørhaug, S., Børset, M., & Haug, M. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.09.003 · Cited by 39
The New Old CD8+ T Cells in the Immune Paradox of Pregnancy
Hardardottir, L., Bazzano, M. V., Glau, L., Gattinoni, L., Köninger, A., Tolosa, E., & Solano, M. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.765730 · Cited by 35
Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D
Linsley, P. S., & Long, S. A. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000488 · Cited by 30
Rothweiler, S., Feldbrügge, L., Jiang, Z. G., Csizmadia, E., Longhi, M. S., Vaid, K. A., Enjyoji, K., Popov, Y. V., & Robson, S. C. (2019) · Purinergic Signalling · doi:10.1007/s11302-019-09664-3 · Cited by 24
Self-citationIL-4 induces a suppressive IL-10-producing CD8+ T cell population via a Cdkn2a-dependent mechanism
Zhao, Y., Zhao, H., Sun, Y., Hao, J., Qi, X., Zhou, X., Wu, Z., Wang, P., Kaech, S. M., Weaver, C. T., et al. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0213064 · Cited by 19
Cited by
Sorted by citations
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A.-T., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 630
CD8+ T cells in the cancer-immunity cycle
Giles, J. R., Globig, A.-M., Kaech, S. M., & Wherry, E. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.005 · Cited by 491
Emerging evidence for adapting radiotherapy to immunotherapy
Galluzzi, L., Aryankalayil, M. J., Coleman, C. N., & Formenti, S. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00782-x · Cited by 389
Cancer cell metabolism and antitumour immunity
Martino, M. D., Rathmell, J. C., Galluzzi, L., & Vanpouille‐Box, C. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01026-4 · Cited by 385
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Polak, R., Zhang, E., & Kuo, C. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00706-6 · Cited by 347
Metadata
- Authors
- Vignali, P. D. A., DePeaux, K., Watson, M. J., Ye, C., Ford, B. R., Lontos, K., McGaa, N. K., Scharping, N. E., Menk, A. V., Robson, S. C., Poholek, A. C., Rivadeneira, D. B., & Delgoffe, G. M.
- Affiliations
- University of Pittsburgh (US)
- University of Pittsburgh Medical Center (US)
- UPMC Hillman Cancer Center (US)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Delgoffe, Greg M.
- ORCID
- Venue
- Nature Immunology
- Published
- 2022-12-21
- Volume
- 24
- Issue
- 2
- Pages
- 267-279
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- PMC
- PMC10402660
- OpenAlex
- W4312095486
- Cited by
- 269
- References
- 52
- Citations by year
- 2026: 49 · 2025: 86 · 2024: 85 · 2023: 49
- FWCI
- 23.21
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research Institute
- Alliance for Cancer Gene Therapy
- University of Pittsburgh (T32CA082084, P30 CA047904)
- National Institutes of Health (SU2C-AACR-IRG-04-16)
- Stand Up To Cancer (SU2C-AACR-IRG-04-16)
- Center for Research Computing, University of Pittsburgh
- National Cancer Institute (F99CA222711, F31CA247129, P50CA121973, F30CA247034, K00CA222711, T32CA082084, P50CA097190, P30CA047904, R01CA277473)
- National Institute of General Medical Sciences (T32GM008208)
- National Institute of Allergy and Infectious Diseases (F31AI149971, DP2AI136598, R01AI171483, R01AI166598)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Keywords
- CD39, tumor hypoxia, exhausted T cells, CD8+ T cells, regulatory T cells, Foxp3, adenosine, immunosuppression, tumor microenvironment, immunotherapy resistance, checkpoint blockade, tumor progression, T cell proliferation inhibition
- MeSH terms
- Hypoxia, Apyrase, Humans, Neoplasms, Antigens, CD, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
